- BioAdaptives (OTC: BDPT), through its PawPa™ division, has launched Regen Dog Chews demonstrating a breakthrough in stem cell production for dogs.
- Clinical trials report a 96.2% increase in circulating stem cells after two weeks and a 281.3% increase after four weeks.
- The new APBAR® rating system allows pet owners to track improvements in their dogs' health with measurable criteria.
BioAdaptives, Inc. (OTC: BDPT) has unveiled remarkable clinical trial results from its pets division, PawPa™, regarding their cutting-edge Regen Dog Chews. The chews are designed to enhance stem cell production in dogs, an effort to significantly improve their overall health and vitality.
In groundbreaking clinical trials, the Regen Dog Chews demonstrated an impressive 96.2% increase in circulating stem cells after just two weeks, escalating to a 281.3% increase after four weeks. This significant boost in stem cell count is a promising development for aging or injured dogs, aiding in tissue repair and offering a pathway to rejuvenated health.
Employing a novel APBAR® rating system, BioAdaptives provides pet owners a tangible way to monitor their dogs' health improvements. APBAR® evaluates Appearance, Performance, Behavior, Attitude, and Responsiveness—mirroring the APGAR score used for newborn humans—to offer a comprehensive view of a dog's wellbeing.
Regen Dog Chews are composed of all-natural ingredients, including beneficial cyanobacteria and adaptogens, which have been clinically proven to bolster coat health, mobility, energy levels, and cognitive function without adverse effects, as confirmed by veterinarian trials.
PawPa™ is inviting pet owners to experience the benefits of Regen Dog Chews, now available through their website, PawPa.com. This advancement marks a significant step forward in pet wellness, making it easier for dogs to maintain vitality through cellular rejuvenation.
